Drugs Used for Treating Primary Aldosteronism

Primary aldosteronism is a form of secondary hypertension caused by autonomous aldosterone production. Excess aldosterone promotes sodium retention, potassium loss, and cardiovascular injury, making appropriate detection and treatment important for blood-pressure control and long-term risk reduction. Treatment commonly involves mineralocorticoid receptor antagonists, particularly spironolactone and eplerenone, while selected patients may receive subtype-directed adrenalectomy after diagnostic evaluation. Drug selection depends on disease subtype, blood-pressure response, potassium status, kidney function, tolerability, comorbidities, and access to specialist care.

Clinical practice is shifting toward greater recognition of primary aldosteronism among people with resistant hypertension, hypokalemia, adrenal incidentaloma, sleep apnea, or early-onset hypertension. More structured screening and confirmatory testing can improve identification of patients who may benefit from targeted therapy. At the treatment level, clinicians are emphasizing individualized dose titration, potassium and renal-function monitoring, and management of endocrine adverse effects. These changes favor care pathways that connect primary care, hypertension specialists, endocrinologists, radiologists, and surgeons rather than relying on medication selection alone.

Artificial intelligence can contribute to primary aldosteronism care by identifying patients whose records contain combinations of resistant hypertension, unexplained hypokalemia, adrenal findings, or repeated medication escalation. Machine-learning tools may also assist with interpretation of biochemical results and imaging workflows, although assay variation, incomplete records, and limited external validation remain important constraints. In drug management, analytics can help flag hyperkalemia risk, declining kidney function, adherence concerns, and inadequate blood-pressure response. These tools should augment specialist judgment, preserve transparent clinical reasoning, and undergo prospective validation before routine deployment.

North America generally benefits from established hypertension and endocrine-specialist networks, but underdiagnosis and fragmented referral pathways remain concerns. Europe combines strong guideline development and specialist expertise with variation in testing access and reimbursement across countries. Asia-Pacific contains advanced tertiary-care systems alongside large populations with limited specialist availability, creating substantial differences in diagnostic and treatment continuity. Latin America faces uneven access to confirmatory testing, adrenal imaging, and long-term monitoring. In the Middle East, concentrated specialist services and expanding hospital capacity coexist with variable awareness. Africa often encounters the greatest constraints in biochemical testing, specialist coverage, medicine availability, and follow-up infrastructure.

ASEAN countries are likely to prioritize scalable screening algorithms, laboratory quality, and affordable access to mineralocorticoid receptor antagonists across mixed health systems. BRICS members face large and diverse patient populations, with opportunities to strengthen referral networks, standardized testing, and domestic clinical capacity. The European Union must manage cross-country variation in reimbursement, laboratory practice, and guideline implementation while supporting coordinated evidence generation. G7 systems can focus on earlier case detection, integrated hypertension services, and digital monitoring for complex patients. GCC countries may leverage concentrated hospital infrastructure and specialist centers, while NATO members broadly face the shared challenge of harmonizing care across civilian, military, and geographically dispersed populations.

Australia, Canada, the United Kingdom, and the United States have established specialist pathways but continue to address missed diagnoses and uneven access outside major centers. France, Germany, Italy, and Spain combine specialist endocrine care with differences in referral patterns, testing protocols, and reimbursement arrangements. Japan and South Korea have strong hospital-based capabilities, while China and India must accommodate substantial regional variation in specialist access, laboratory standardization, and continuity of care. Brazil and Mexico face disparities between urban tertiary hospitals and other settings. Russia’s treatment environment is shaped by geographic scale, referral capacity, and medicine access. Across all listed countries, safer use depends on reliable biochemical assessment, appropriate subtype evaluation, and monitoring of potassium and renal function.

Industry leaders should support standardized screening and referral protocols for high-risk hypertension populations, while avoiding indiscriminate testing that may increase false-positive results. Clinical programs should invest in laboratory quality assurance, validated aldosterone and renin measurement, clear medication-interference protocols, and coordinated confirmatory testing. Treatment services should pair mineralocorticoid receptor antagonist prescribing with structured potassium, kidney-function, blood-pressure, and adherence monitoring. Education should address both clinicians and patients, including endocrine adverse effects and the importance of follow-up. Digital and artificial-intelligence tools should be introduced through privacy-preserving pilots with measurable clinical endpoints, human oversight, and transparent performance evaluation.

This executive summary uses a qualitative synthesis framework focused on established clinical concepts, treatment pathways, health-system conditions, and implementation considerations for drugs used to treat primary aldosteronism. The analysis distinguishes pharmacological management from diagnostic confirmation and subtype-directed intervention. Regional, group, and country observations are framed as system-level considerations rather than numerical comparisons. Claims are limited to widely documented clinical and operational patterns, with attention to medication safety, laboratory requirements, access barriers, and the appropriate role of emerging digital tools. No market estimates, market shares, forecasts, or company-specific claims are used.

Primary aldosteronism treatment is shaped as much by diagnostic recognition and monitoring capacity as by the availability of established medicines. Mineralocorticoid receptor antagonists remain central for patients managed medically, while selected patients may benefit from a pathway that identifies surgically remediable disease. The most durable improvements will come from earlier case finding, reliable biochemical testing, coordinated specialist referral, equitable access, and disciplined safety monitoring. Regional and national strategies should adapt these principles to local laboratory capacity, workforce distribution, reimbursement, and continuity-of-care requirements.